Amiloride derivatives enhance insulin release in pancreatic islets from diabetic mice

1472-6823-5-9 1472-6823 Research article Amiloride derivatives enhance insulin release in pancreatic islets from diabetic mice Gunawardana C Subhadra subhadra.gunawardana@vanderbilt.edu Head W Steven Steven.Head@vanderbilt.edu Piston W David Dave.Piston@vanderbilt.edu

Department of Molecular Physiology and Biophysics, 702 Light Hall, Vanderbilt University, Nashville, TN 37232, USA

BMC Endocrine Disorders 1472-6823 2005 5 1 9 http://www.biomedcentral.com/1472-6823/5/9 16336655 10.1186/1472-6823-5-9 30 6 2005 08 12 2005 08 12 2005 2005 Gunawardana et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Amiloride derivatives, commonly used for their diuretic and antihypertensive properties, can also cause a sustained but reversible decrease of intracellular pH (pH_i). Using dimethyl amiloride (DMA) on normal rodent pancreatic islets, we previously demonstrated the critical influence of islet pH_ion insulin secretion. Nutrient-stimulated insulin secretion (NSIS) requires a specific pH_i-range, and is dramatically enhanced by forced intracellular acidification with DMA. Furthermore, DMA can enable certain non-secretagogues to stimulate insulin secretion, and induce time-dependent potentiation (TDP) of insulin release in mouse islets where this function is normally absent. The present study was performed to determine whether pH_i-manipulation could correct the secretory defect in islets isolated from mice with type 2 diabetes.

Methods

Using two mouse models of type 2 diabetes, we compared a) pHi-regulation, and b) NSIS with and without treatment with amiloride derivatives, in islets isolated from diabetic mice and wild type mice.

Results

A majority of the islets from the diabetic mice showed a slightly elevated basal pH_iand/or poor recovery from acid/base load. DMA treatment produced a significant increase of NSIS in islets from the diabetic models. DMA also enabled glucose to induce TDP in the islets from diabetic mice, albeit to a lesser degree than in normal islets.

Conclusion

Islets from diabetic mice show some mis-regulation of intracellular pH, and their secretory capacity is consistently enhanced by DMA/amiloride. Thus, amiloride derivatives show promise as potential therapeutic agents for type 2 diabetes.

Background

As is widely known, nutrient-stimulated insulin secretory response in the pancreatic β cell consists of three distinct components. These include: a) an initial peak (first phase) triggered by Ca²⁺, b) augmentation of the Ca²⁺-triggered response (second phase), and c) a memory that persists after removal of the nutrient, causing enhancement of subsequent secretory responses (time-dependent potentiation) 1 2 3 4 . The first phase of the insulin response is initiated by ATP derived from glucose metabolism, which leads to membrane depolarization through closure of ATP-dependent K⁺channels (K_ATPchannels) and consequent entry of extracellular Ca²⁺through voltage-gated Ca²⁺channels. This influx of Ca²⁺triggers the release of a small pool of secretory granules, thus producing the initial peak of the insulin response 1 . This peak is followed by a sustained second phase of insulin release that lasts through the duration of exposure to the nutrient, mediated through augmentation of the Ca²⁺-triggered first-phase response 1 . Time-dependent potentiation (TDP), a positive memory induced during this acute response, magnifies subsequent secretory responses to all secretagogues 2 4 5 6 .

Islet intracellular pH (pH_i) exerts a strong influence on all aspects of the insulin secretory response, as well as other related functions such as Ca²⁺influx and K⁺retention 7 8 9 10 11 12 13 14 15 16 17 . These functions are enhanced by a decrease of pH_i, and inhibited by an increase of pH_i. Our recent work on isolated mouse islets has demonstrated that NSIS requires a specific pH_i-range, and is greatly enhanced by decreasing islet pH_iusing DMA 7 . The basal pH_iin mouse islets ranges from 6.9 to 7.2. Treatment with DMA, an inhibitor of the Na⁺/H⁺exchanger, brings islet pH_ito the lower range of 6.4–6.8. This decrease of pH_iin turn causes a dramatic enhancement in insulin secretion induced by metabolic secretagogues, and enables certain non-secretagogues to stimulate insulin release 7 . Another remarkable effect of DMA is to enable glucose to induce TDP, a function normally absent in mouse islets 7 . Hence, DMA has a consistently favorable effect on all aspects of the insulin response in isolated mouse islets. Previous studies have shown similarly positive effects of amiloride derivatives on insulin secretion in other species as well 8 12 13 14 16 .

Thus, it is possible that: a) a mis-regulation of intracellular pH may contribute to the defect in insulin secretion found in type 2 diabetes; and b) Forcing the islet pH_ito a lower range may correct/improve this secretory defect. To test these hypotheses, we monitored insulin secretion and islet pH_iin two mouse models of type 2 diabetes. Regulation of islet pH_iand the influence of amiloride derivatives on insulin secretion and TDP in isolated islets from diabetic mice were compared to similar parameters in islets from wild type mice.

Results from both models of type 2 diabetes demonstrate some abnormalities in pH_i-regulation, and consistently favorable effects of DMA/amiloride on both direct insulin secretion and TDP in isolated islets. These results suggest the potential value of amiloride derivatives in treatment of type 2 diabetes

Methods

Animals

Mouse models of type 2 diabetes i.e. strains NON/LtJ (Diabetic NON mice; stock number 002423) and KK/Upj-A<y>/J (Diabetic KK mice; stock number 002468) were purchased from Jackson Laboratories, Bar Harbor, ME. C57BL6 mice (Harlan Sprague Dawley, Indianapolis, IN) were used as wild type controls. All animals were males, and the control mice were 7–9 weeks of age. The diabetic KK and NON mice were used at 9–20 weeks and 5–9 months, respectively, in order to allow time for NIDDM to develop. The body weight range was 20–30 g for the control mice, and 40–80 g for the diabetic mice. The animals were fed standard laboratory chow, and cared for according to the guidelines of the Vanderbilt Institutional Animal Care and Use Committee.

Media

Pancreatic islets were isolated in Hanks Balanced Salt solution, and HEPES-buffered Krebs Ringer Bicarbonate solution (KRBH) was used for the static incubations in secretion experiments. The components of KRBH are as follows: 128.8 mM NaCl; 4.8 mM KCl; 1.2 mM KH₂PO₄; 1.2 mM MgSO₄; 2.5 mM CaCl₂; 5 mM NaHCO₃^-; 10 mM HEPES; and 0.1% bovine serum albumin. The medium pH was maintained at 7.4. Basal KRBH used for pre-incubation and non-stimulated controls contained 2.8 mM glucose, while the stimulating media contained either 16.7 mM glucose, or other secretagogues as indicated in the presence of 2.8 mM glucose. The non-glucose secretagogues included 20 mM alpha-ketoisocaproate (αKIC), or 20 mM 2-amino-bicyclo[2,2,1]heptane-2-carboxylic acid (BCH). αKIC, a mitochondrially-metabolized secretagogue, is a metabolic product of the amino acid leucine. BCH is a non-metabolizable analog of leucine, and stimulates insulin secretion presumably through allosteric activation of mitochondrial dehydrogenases. For forced decrease of islet pH_i, 40 μM DMA was added to the medium to produce intracellular acidification. In preparation for imaging experiments, islets were cultured in RPMI 1640 culture medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 0.1 g/L streptomycin and 11 mM glucose.

Isolation of islets

A modified version of the collagenase digestion method described by Lacy and Kostianovsky 18 was used. Mice were terminally anesthetized with intra-peritoneal injection of Ketamine/Xylazine (80/20 mg/Kg). Pancreas was removed, placed in ice-cold Hanks solution and minced with scissors. Collagenase (3 mg/ml) was added and the mixture shaken in a 37°C water bath until the tissue was adequately digested. The mixture was then centrifuged, supernatant removed and the pellet re-suspended in Hanks solution. Centrifugation and re-suspension were repeated several times to remove exocrine tissue. The final pellet was re-suspended either in basal KRBH medium for secretion experiments or RPMI medium for islet culture. Islets were hand picked under a stereomicroscope.

Culture of islets

The method described by Arkhammar et al. 1998 19 was used with minor modifications 7 20 21 . 35 mm culture dishes with glass-bottomed wells (Mat-Tek corporation) were used. The dishes were pre-prepared by coating the wells with human extracellular matrix (BD Biosciences). Freshly isolated islets were placed carefully in each well, covered with RPMI medium containing 11 mM glucose, and cultured at 37°C in 95% O₂and 5% CO₂. Under these conditions, the cells in the islet spread out within 14 days, greatly reducing the islet thickness and making it particularly suitable for imaging with confocal microscopy. Islets cultured under these conditions exhibit normal responses of Ca²⁺, NAD(P)H and insulin release to glucose stimulation, as described in previous studies 19 20 21 and confirmed in our preliminary experiments.

Intracellular pH measurements

As described in our previous studies 7 , islet pH_iwas monitored by confocal microscopy, using carboxy-seminaphthorhodofluor-5 (SNARF5) 22 , a pH-sensitive fluorescent indicator. Prior to imaging, cultured islets were maintained in RPMI medium containing 5 mM glucose for at least 48 hours. On the day of the experiment, RPMI medium was removed, and islets were washed and placed in basal KRBH medium. SNARF5-AM (5 μM final concentration) was added and incubated for one hour at 37°C. Loaded islets were placed on a warmed stage in a humidified and temperature-controlled chamber at 37°C, and monitored with a F-Fluar 40 × 1.3 NA oil immersion lens of a LSM510 confocal laser-scanning microscope (Zeiss). Islets were excited at 514 nm with an argon laser, and the emission fluorescence was collected in the band-widths 568–589 nm and 621–643 nm (peak emission at 580 and 630 nm) using the Meta detector (Zeiss). Time-series images (2.56 μs/pixel) were collected for 5–20 minutes as was suitable for each experiment. A stable baseline was obtained before the actual recording for each experimental condition started. LSM software was used to calculate the ratio between the two emission fluorescence values from selected well-loaded regions in each islet. This ratio was proportional to the islet pH_i. The results were analyzed using LSM software, Graphpad Prism, and Microsoft Excel. One representative recording for each experimental condition is shown in the results section, and the value n denotes the number of recordings done with different islets for each condition. A standard curve was prepared by fixing the islet pH_iat known values (ranging from 5.5 to 9, with 5–10 islets for each pH), using a KRBH medium containing 100 mM K⁺and 20 mM nigericin to equilibrate the pH inside and outside cells.

Secretion measurements

All incubations were done in a 37°C water bath. Freshly isolated islets were pre-incubated for one hour in basal KRBH containing 2.8 mM glucose. Islets were then divided into groups and stimulated with different compounds as indicated in the results section, for one hour. Control group was maintained in basal glucose. Each group consisted of 4–5 tubes containing 4 islets per tube. At the end of the stimulation period, samples were collected for insulin measurement by radio-immuno-assay (performed by the DRTC Core facility at Vanderbilt University). Islet insulin content was measured after freezing islets overnight in 1% Triton-X. Insulin secretion was expressed as fractional release, i.e. the percentage of total insulin content released over the period of stimulation. In the experiments monitoring TDP, after pre-incubation islets were exposed to high (16.7 mM) glucose with or without intracellular acidification for 40 minutes, while the control group was exposed to basal glucose. Subsequently all groups were rested in basal glucose for 20 minutes, and stimulated with high glucose for 40 minutes prior to collection of samples for insulin assay. The value n denotes the number of times each experiment was repeated using islets from different mice.

In vivo treatment

Effect of oral treatment with amiloride derivatives on insulin secretion from isolated islets was monitored in diabetic NON mice. Mice were divided into three groups, i.e. DMA-treated; amiloride treated; and untreated control. DMA (estimated dose: 1 mg/Kg/day) or amiloride (estimated dose: 5 mg/Kg/day) was administered in drinking water to the test groups for one week. At the end of the week mice were euthanized and insulin secretion was measured from isolated islets as described earlier.

Statistical Analysis

Values are expressed as mean ± SEM. Groups were compared using paired Student's t test. In secretion studies, n denotes the number of times each experiment was repeated with islets from different mice. In imaging experiments for pH_i, n denotes the number of islets imaged for each condition.

Results and Discussion

The influence of islet pH_ion insulin secretion has been reported in a number of studies 7 8 9 10 11 12 13 14 15 16 17 . Our recent work in isolated mouse islets has demonstrated the critical dependence of NSIS on an appropriate pH_i, and the ability of pH_i-lowering agents to dramatically enhance all components of the insulin response 7 . Type 2 diabetes is characterized by a progressive decline in insulin secretion in the β cell in addition to peripheral insulin resistance. Since islet pH_iplays a critical role in NSIS in normal islets, it is likely that a mis-regulation of pH_imay contribute to this secretory defect, which could be corrected through manipulation of islet pH_i. Thus, the present study was aimed at exploring the beneficial effects of pH_i-lowering drugs on insulin release from isolated islets in type 2 diabetes.

We used two mouse models of type 2 diabetes obtained from Jackson laboratories: the KK/Upj-A<y>/J mice (Diabetic KK mice) and the NON/LtJ mice (Diabetic NON mice). Diabetic KK mice are a congenic strain developed as a model for obesity and type 2 diabetes. They develop obesity, hyperglycemia (300–500 mg/dl), insulin resistance and hyperinsulinemia (10 ng/ml) by 8 weeks of age 23 . Diabetic NON mice are an inbred strain, originally developed as a control strain for the well-known IDDM model of NOD/LtJ. NON mice are genetically related closely to NOD mice but have a diabetes resistant MHC haplotype H2^nb1(K^b, A^nb1, E^k, D^b), and are homozygous for the retinal degeneration allele Pde6b^rd1. NON mice have genes predisposing to type 2 diabetes, evidenced by early impaired glucose tolerance and development of maturity onset obesity and hypoinsulinemia. At 20 weeks of age NON males exceed 40 g in body weight, with blood glucose and insulin levels reported around 200 mg/dl and 1 ng/ml, respectively 24 .

Basal intracellular pH in wild type (WT) mouse islets ranges from 6.9 to 7.2. The strong buffering mechanisms in the β cells ensure quick recovery from the pH_i-changes induced by treatment with a weak acid or weak base (acid/base load) 7 8 , and Fig. 1A]. Approximately 70% of the islets isolated from diabetic mice showed abnormalities in their pH_i-regulation. In diabetic KK mice, the basal islet pH was higher than that in WT mice (Fig. 1B). Islets isolated from both diabetic strains showed slower recovery from acid/base load, sometimes followed by overcompensation (Fig. 1:B&C). Thus, type 2 diabetes is associated with some mis-regulation of islet pH_i. Regardless of whether these abnormalities play a role in insulin secretion, treatment with amiloride derivatives is likely to improve NSIS in diabetes.

Figure 1

Islets from diabetic mice show abnormalities in pH_iregulation

Islets from diabetic mice show abnormalities in pH_iregulation: Cultured islets loaded with SNARF5-AM were excited at 514 nm, and emission fluorescence was collected at 580 and 630 nm. Islet pH_iwas calculated from the ratio of emission fluorescence. Acetate (40 mM) or NH₄Cl (5 mM) was added where indicated. One representative recording for each condition is shown. 10–20 islets were imaged for each condition. A. Wild type islets: Basal pH_irange 6.9–7.1. Fast recovery from drastic pH_i-change produced by acid or base load. B. Islets from diabetic KK mice: Basal pH_irange 7.3–7.5. Recovery from acid load is slower. Recovery from base load is followed by overcompensation. C. Islets from diabetic NON mice: Basal pH_isimilar to wild type controls. Response to base load is slower. Recovery is from acid/base load is followed by overcompensation.

DMA normally produces a dramatic increase in nutrient stimulated insulin secretion from isolated islets 7 8 . In this study we monitored the effect of DMA on the insulin response to glucose and αKIC in islets isolated from diabetic mice. DMA consistently enhanced insulin secretion in response to both secretagogues (glucose and αKIC), in islets from both diabetic models as well as from WT mice (Fig. 2).

Figure 2

DMA enhances insulin secretion stimulated by glucose and αKIC (alpha-ketoisocaproate), in islets isolated from both normal and diabetic mice

DMA enhances insulin secretion stimulated by glucose and αKIC (alpha-ketoisocaproate), in islets isolated from both normal and diabetic mice: Groups of islets were treated with different secretagogues with and without intracellular acidification produced by 40 μM DMA (denoted in red). Insulin secretion was measured at the end of the 60-minute stimulation period. Insulin secretion produced by both 16.7 mM glucose and 20 mM αKIC is significantly enhanced by intracellular acidification, in all three mouse strains (n = 10; * = p < 0.001). Values in the figure are expressed as fractional release (% of total insulin content released over the 60-minute period). The corresponding absolute amounts (ng/ml) for each condition from left to right are: 0.46 ± 0.1, 4.04 ± 0.44, 6.37 ± 0.71, 3.39 ± 0.72, 31.97 ± 2.58, 46.12 ± 5.51, 7.5 ± 0.9, 22.4 ± 3.2, 29.87 ± 5.35, 1.24 ± 0.18, 2.05 ± 0.3, 17.12 ± 2.11, 34.73 ± 4.053, 11.8 ± 1.38 and 13.76 ± 1.77.

Since in-vitro treatment of isolated islets with DMA enhances NSIS, we next tested the corresponding effects of oral administration of DMA or amiloride to diabetic mice. Diabetic KK mice, being hyperinsulinemic, exhibited above-normal NSIS in the in-vitro experiments. Therefore, the in-vivo administration of amiloride was done only in the diabetic NON mice, which exhibited a significant impairment in NSIS. Diabetic NON mice were divided into three groups, i.e. DMA-treated; amiloride treated; and untreated control. DMA (1 mg/Kg/day) or amiloride (5 mg/Kg/day) was administered in drinking water to the test groups for one week prior to isolation of islets for insulin measurement. Mice were housed two to a cage and their behavior was monitored. All animals were observed to drink frequently, and drug dose was calculated using estimated water intake. Islets isolated from mice pre-treated with DMA or amiloride consistently exhibited a significantly stronger insulin response to all three secretagogues tested (16.7 mM glucose, 20 mM αKIC or BCH) (Fig. 3). Thus, oral treatment with low doses of DMA or amiloride enhances insulin release in islets from diabetic NON mice, with no conspicuous adverse effects on fluid or blood pressure regulation.

Figure 3

Prior oral treatment with DMA and amiloride enhances insulin secretion in isolated islets from diabetic NON mice

Prior oral treatment with DMA and amiloride enhances insulin secretion in isolated islets from diabetic NON mice: Islets were isolated from diabetic NON mice previously treated with DMA (estimated dose: 1 mg/kg/day) or amiloride (estimated dose: 5 mg/kg/day) in drinking water for a week. Groups of islets were treated with different secretagogues as indicated, and insulin secretion was measured at the end of the 60-minute stimulation period. Prior oral treatment with amiloride derivatives significantly enhances insulin secretion stimulated by each secretagogue. G = mM glucose; αKIC = alpha-ketoisocaproate (20 mM); BCH = 2-amino-bicyclo[2,2,1]heptane-2-carboxylic acid (20 mM); n = 5; * = p < 0.001 and # = p < 0.05, compared with each corresponding untreated control group. Values in the figure are expressed as fractional release (% of total insulin content released over the 60-minute period). The corresponding absolute amounts (ng/ml) for each condition from left to right are: 9.5 ± 1.29, 12.4 ± 3.06, 4.5 ± 1.05, 18.81 ± 2.65, 24.73 ± 1.96, 19.02 ± 3.02, 11.8 ± 1.38, 8.0 ± .66, 7.5 ± 0.96, 5.98 ± 1.48, 9.07 ± 2.1, and 8.92 ± 1.95

One problem we encountered with the diabetic NON mice was that the basal insulin release from isolated islets was high. Consequently the defect in NSIS was not obvious due to the elevated basal insulin release. However, the increase in insulin release produced by high glucose in NON mice (2 fold or less compared to basal glucose) is much smaller than that in the other two strains (10–12 fold compared to basal glucose), and non-glucose secretagogues such as αKIC and BCH do not stimulate above-basal insulin release in NON islets. Furthermore, the increased basal insulin release found in isolated islets may not directly translate into elevated plasma insulin, because the islet number per pancreas is diminished in NON mice, and the islets show abnormalities in size and shape as well. Thus, NON mice have a marked secretory defect, which is corrected to a significant degree by amiloride derivatives.

DMA treatment also unmasks TDP, a function normally absent in mouse islets 7 . TDP is defined as an enhancement of the insulin secretory response in the β cell, induced by a previous exposure to glucose or certain other secretagogues. TDP can be measured by comparing the glucose-induced insulin response in islets previously exposed high glucose or basal glucose. As shown in figure 4, treatment with DMA enables glucose to induce TDP in islets from both diabetic strains, albeit to a lesser degree than in WT islets.

Figure 4

DMA enables glucose to induce TDP in islets from both normal and diabetic mice

DMA enables glucose to induce TDP in islets from both normal and diabetic mice: Insulin secretion in response to high glucose (16.7 mM) is shown, in groups of islets previously exposed to glucose with and without intracellular acidification produced by 40 μM DMA (denoted in red). DMA treatment enables glucose to induce TDP both in wild type controls (left) and each strain of type 2 diabetes (Right). G = mM glucose; n = 5; * = p < 0.001 and # = p < 0.05, compared with each corresponding untreated control. Values in the figure are expressed as fractional release (% of total insulin content released over the final 40-minute period in response to 16.7 mM glucose). The corresponding absolute amounts (ng/ml) for each condition from left to right are: 2.88 ± 0.57, 5.3 ± 0.76, 8.5 ± 0.93, 11.96 ± 2.14, 20.32 ± 6.12, 39.68 ± 5.69, 15.2 ± 3.23, 15.79 ± 2.59, and 19.79 ± 3.41.

These results show that islets isolated from diabetic mice exhibit some abnormalities in their pH_i-regulation, and that several aspects of their insulin response are significantly improved by amiloride derivatives. Thus, treatment with low doses of amiloride derivatives shows promise in the therapy of type 2 diabetes. The next step is to determine whether these drugs can normalize blood glucose and insulin levels. These in vivo studies will be conducted in a more suitable model of type 2 diabetes with a more pronounced secretory defect, with parallel in-vitro work on human islets. Currently we are looking into suitable rodent models of NIDDM, and one mouse model that shows promise is the strain GK^lox/w+ Rip-Cre developed by another group at Vanderbilt 25 . The current study shows the potential value of amiloride in improving insulin release in diabetes, and recently-developed better amiloride analogs such as pyrazinoylguanidine 26 27 may be good candidates for correcting the secretory defect in human diabetes.

Conclusion

This study demonstrates the presence of abnormalities in islet pH_i-regulation in type 2 diabetes, and the ability of DMA and amiloride to significantly improve NSIS in isolated islets from diabetic mice. Thus, treatment with low doses of amiloride derivatives has potential therapeutic value for enhancing NSIS in human diabetes, and merits further investigation through in vivo studies.

List of Abbreviations

NSIS: nutrient-stimulated insulin secretion; DMA: dimethyl amiloride; pH_i= intracellular pH; TDP: time-dependent potentiation; KRBH: HEPES-buffered Krebs Ringer Bicarbonate solution; αKIC: alpha-ketoisocaproate; BCH: 2-amino-bicyclo[2,2,1]heptane-2-carboxylic acid; SNARF5-AM: carboxy-seminaphthorhodofluor-5 acetoxy methyl ester; SEM: standard error of mean; WT: wild type; Diabetic KK mice: KK/Upj-A<y>/J mice; Diabetic NON mice: NON/LtJ mice; MHC: Major histocompatibility complex.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

SCG designed the study and carried out the insulin secretion experiments, in-vivo treatments and intracellular pH-measurements. WSH prepared the cultured islets used in pH_imeasurements. DWP participated in the design and coordination of the study.

Acknowledgements

This work was supported by the NIH grants DK67821 (to SCG) and DK53434 (to DWP). Some assays and data analysis were performed in part through the use of the DRTC Hormone Core Resource and VUMC Cell Imaging Core Resource (supported by NIH grants CA68485, DK20593 and DK58404).

Glucose-stimulated signaling pathways in biphasic insulin secretion Straub SG Sharp GW Diabetes Metab Res Rev 2002 18 451 463 10.1002/dmrr.329 12469359 Modeling phasic insulin release: immediate and time-dependent effects of glucose Nesher R Cerasi E Diabetes 2002 51 Suppl 1 S53 S59 11815459 Signals and pools underlying biphasic insulin secretion Henquin JC Ishiyama N Nenquin M Ravier MA Jonas JC Diabetes 2002 51 S60 S67 11815460 Biphasic insulin release as the expression of combined inhibitory and potentiating effects of glucose Nesher R Cerasi E Endocrinology 1987 121 1017 1024 3304974 Potentiation of insulin release by glucose in man. II. Role of the insulin response, and enhancement of stimuli other than glucose Cerasi E Acta Endocrinologica 1975 79 502 510 1173505 Effects of priming with D-glucose on insulin secretion from rat pancreatic islets: Increased responsiveness to other secretagogues Grill V Rundfeldt M Endocrinology 1979 105 980 987 89958 Nutrient-stimulated insulin secretion in mouse islets is critically dependent on intracellular pH Gunawardana SC Rocheleau JV Head WS Piston DW BMC Endocr Disord 2004 4 1 1 434517 15193158 10.1186/1472-6823-4-1 Intracellular pH plays a critical role in glucose-induced time-dependent potentiation of insulin release in rat islets Gunawardana SC Sharp GW Diabetes 2002 51 105 113 11756329 Role of pH as a transduction device in triggering electrical and secretory responses in islet B cells Pace CS Federation Proceedings 1984 43 2379 2384 6327397 Modification of glucose-induced insulin release by alteration of pH Smith JS Pace CS Diabetes 1983 2 61 66 Stimulus-secretion coupling in beta-cells: modulation by pH Pace CS Tarvin JT Smith JS Am J Physiol 1983 244 E3 E18 6295181 Is intracellular pH a coupling factor in nutrient-stimulated pancreatic islets? Best L Bone EA Meats JE Tomlinson S J Mol Endocrinol 1988 1 33 38 3076778 Modulation by cytosolic pH of calcium and rubidium fluxes in rat pancreatic islets Best L Yates AP Gordon C Tomlinson S Biochem Pharmacol 1988 37 4611 4615 10.1016/0006-2952(88)90328-0 3060124 Changes in 2',7'-bis(carboxyethyl) 5'(6')-carboxyflurescein, fura-2 and autofluorescence in intact rat pancreatic islets in response to nutrients and non-nutrients Best L Elliot AC Mol Cel Endocrinol 1995 111 191 198 10.1016/0303-7207(95)03568-R The stimulus-secretion coupling of glucose-induced insulin release; Metabolic and functional effects of NH4+ in rat islets Sener A Hutton JC Kawazu S Boschero AC Somers G Devis G Herchuelz A Malaisse WJ J Clin Invest 1978 62 868 878 371839 29912 Na+-H+ exchange in the process of glucose-induced insulin release from the pancreatic B-cell. Effects of amiloride on 86Rb, 45Ca fluxes and insulin release Lebrun P Van Ganse E Juvent M Deleers M Herchelz A Biochim Biophys Acta 1982 886 448 456 Effects of nutrient and non-nutrient stimuli on cytosolic pH in cultured insulinoma (HIT-T15) cells Lynch AM Meats JE Best L Tomlinson S Biochim Biophys Acta 1989 1012 166 170 10.1016/0167-4889(89)90091-8 2545265 Method for the isolation of intact islets of Langerhans from the rat pancreas Lacy PE Kostianovsky M Diabetes 1967 16 35 39 5333500 Pancreatic islets cultured on extracellular matrix: An excellent preparation for microfluorometry Arkhammar POG Terry BR Kofod H Thastrup O Methods Cell Sci 1998 19 255 268 10.1023/A:1009712630494 Pancreatic islet beta-cells transiently metabolize pyruvate Rocheleau JV Head WS Nicholson WE Powers AC Piston DW J Biol Chem 2002 277 30914 30920 10.1074/jbc.M202314200 12070148 Separation of the glucose-stimulated cytoplasmic and mitochondrial NAD(P)H responses in pancreatic islet beta cells Patterson GH Knobel SM Arkhammar P Thastrup O Piston DW Proc Natl Acad Sci USA 2000 97 5203 5207 25806 10792038 10.1073/pnas.090098797 Synthesis and photophysical properties of new fluorinated benzo(<it>c</it>)xanthene dyes as intracellular pH indicators Liu J Diwu Z Leung WY Bioorg Med Chem Let 2001 11 2903 2905 10.1016/S0960-894X(01)00595-9 JAXR Mice Data Sheet: Jackson Laboratory Database http://jaxmice.jax.org/jaxmice-cgi/jaxmicedb.cgi?objtype=pricedetail&stock=002468&dest=N JAXR Mice Data Sheet: Jackson Laboratory Database http://jaxmice.jax.org/jaxmice-cgi/jaxmicedb.cgi?objtype=pricedetail&stock=002423&dest=N Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase Postic C Shiota M Niswender KD Jetton TL Chen Y Moates JM Shelton KD Lindner J Cherrington AD Magnuson MA J Biol Chem 1999 274 1 305 315 10.1074/jbc.274.1.305 9867845 Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus Vesell ES Beyer KH Jr Toxicolog 2000 144 1–3 5 11 10.1016/S0300-483X(99)00213-9 Studies on pyrazinoylguanidine. 7. Effects of single oral doses in normal human subjects Vesell ES Beyer KH Jr Pharmacology 1999 58 3 140 146 10.1159/000028276 9925970

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1472-6823/5/9/prepub